The parent company took the decision as MediCult A/S – a leader in Assisted Reproductive Technologies – did not reach the required share threshold within the set timeframe – as quoted in ca.sys-con.com.
Merck Serono offers a portfolio of fertility drugs to infertile couples at every stage of the reproductive cycle – from follicular development to early pregnancy, and produces the recombinant versions of the hormones required in the treatment of infertility namely GONAL-f FbM, Luveris, Cetrotide, Ovitrelle, Crinone and Pergoveris.
Richard Douge, Executive Vice President Global Marketing at Merck Serono said: “Merck Serono has a proud heritage of leadership in the field of fertility and will actively pursue opportunities that will contribute to bring further innovation to physicians and patients, and increase the success rate of fertility treatments.”